Akoya Biosciences, Inc.
AKYA
$1.16
$0.021.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 79.96M | 81.67M | 86.82M | 93.22M | 93.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.96M | 81.67M | 86.82M | 93.22M | 93.57M |
| Cost of Revenue | 30.59M | 33.79M | 36.71M | 39.56M | 41.18M |
| Gross Profit | 49.37M | 47.88M | 50.11M | 53.66M | 52.39M |
| SG&A Expenses | 67.03M | 69.32M | 73.71M | 79.29M | 84.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.37M | 122.86M | 131.09M | 141.36M | 149.43M |
| Operating Income | -37.41M | -41.18M | -44.28M | -48.15M | -55.86M |
| Income Before Tax | -47.40M | -55.22M | -57.84M | -60.25M | -67.93M |
| Income Tax Expenses | 131.00K | 146.00K | 132.00K | 103.00K | 74.00K |
| Earnings from Continuing Operations | -47.53 | -55.37 | -57.97 | -60.35 | -68.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.53M | -55.37M | -57.97M | -60.35M | -68.01M |
| EBIT | -37.41M | -41.18M | -44.28M | -48.15M | -55.86M |
| EBITDA | -30.01M | -33.53M | -36.37M | -39.49M | -47.04M |
| EPS Basic | -0.96 | -1.12 | -1.18 | -1.23 | -1.47 |
| Normalized Basic EPS | -0.60 | -0.65 | -0.66 | -0.70 | -0.84 |
| EPS Diluted | -0.96 | -1.12 | -1.18 | -1.23 | -1.47 |
| Normalized Diluted EPS | -0.60 | -0.65 | -0.66 | -0.70 | -0.84 |
| Average Basic Shares Outstanding | 198.15M | 197.67M | 197.20M | 196.67M | 187.89M |
| Average Diluted Shares Outstanding | 198.15M | 197.67M | 197.20M | 196.67M | 187.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |